Who Owns Paragon 28?
Paragon 28 is owned by Zimmer Biomet Holdings, Inc. (NYSE: ZBH), a global medical technology company headquartered in Warsaw, Indiana. Zimmer Biomet acquired Paragon 28 on April 21, 2025 for approximately $1.1 billion in cash. Paragon 28 operates as a wholly-owned subsidiary focused on foot and ankle orthopedic surgical devices, based in Englewood, Colorado.
Parent Company
Acquired
2025
Status
Publicly Traded
Headquarters
Paragon 28 Timeline
GlobalOfficial Website
Who Owns Paragon 28?
- Parent Company: Zimmer Biomet Holdings, Inc.
- Ownership Type: Wholly owned
- Acquisition Year: 2025
- Company Type: Publicly Traded
- Stock Ticker: NYSE: ZBH
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Paragon 28 | Zimmer Biomet Holdings, Inc. | Wholly owned |
Where to Buy
Disclosure: We may earn commission from purchases
Paragon 28 on AmazonHistory of Paragon 28
- Founded: 2010
- Founders: Albert DaCosta
- Acquired by Zimmer Biomet Holdings, Inc.: 2025
Albert DaCosta founded Paragon 28 in 2010 in Englewood, Colorado. The company was named after the 28 bones in the human foot, reflecting its singular focus on foot and ankle orthopedic surgery. DaCosta had previously worked in the orthopedic device industry and identified foot and ankle as an underserved specialty within musculoskeletal care.
The company began by developing surgical implants and instruments for common foot and ankle procedures including bunion correction, hammertoe fixation, and fracture repair. Paragon 28 designed its products with input from orthopedic surgeons specializing in foot and ankle surgery, targeting procedural approaches that simplified complex operations.
In its first decade, Paragon 28 expanded its product portfolio to cover a wide range of foot and ankle ailments: fracture fixation, forefoot procedures, ankle reconstruction, progressive collapsing foot deformity (PCFD or flatfoot), Charcot foot, and orthobiologics. The company developed the Gorilla plating system, the Phantom intramedullary nail system, and the APEX 3D Total Ankle Replacement System as its flagship product lines.
Paragon 28 went public on the New York Stock Exchange in 2021 under the ticker symbol FNA. The IPO raised capital for product development and commercial expansion. The company reported net revenue of $255.9 to $256.2 million for full year 2024, representing 18.2% to 18.4% reported growth over the prior fiscal year. This double-digit growth rate was a key factor in Zimmer Biomet's acquisition interest.
Zimmer Biomet announced the definitive agreement to acquire Paragon 28 on January 28, 2025. The deal was unanimously approved by both companies' boards of directors. The acquisition closed on April 21, 2025, and Paragon 28 was delisted from the NYSE.
Following the acquisition, Zimmer Biomet continued launching new Paragon 28 products. In October 2025, the company launched the Gorilla Pilon Fusion Plating System and the Phantom TTC Trauma Nail for complex trauma cases. In January 2026, Zimmer Biomet launched the Brachiator Mini-Rail External Fixation System for small bone reconstruction in the foot and ankle. In February 2026, the Phantom Curved TTC Nail System was introduced for hindfoot fusion. In June 2026, the SPIDER MONKEY TTT Bone Transport System was launched for transverse tibial transport procedures.
Zimmer Biomet CEO Ivan Tornos stated at a Morgan Stanley event in September 2025 that he expected to double the size of the SET business over five to seven years through organic and inorganic means, with Paragon 28 as the platform for that growth.
About Zimmer Biomet Holdings, Inc.
Is Zimmer Biomet publicly traded?
Yes. Zimmer Biomet Holdings, Inc. trades on the New York Stock Exchange under the ticker symbol ZBH. The company is also listed on the SIX Swiss Exchange. Zimmer Biomet is a component of the S&P 500 index. The company was first spun off from Bristol Myers Squibb in August 2001 and has been independently traded since then.
When was Zimmer Biomet founded?
Zimmer Biomet traces its origins to 1927, when Justin O. Zimmer founded Zimmer Manufacturing Company in Warsaw, Indiana, to produce aluminum splints. The modern Zimmer Biomet Holdings, Inc. was incorporated in Delaware in 2001 and was formed through the acquisition of Biomet, Inc. in June 2015, at which point the company changed its name from Zimmer Holdings, Inc. to Zimmer Biomet Holdings, Inc.
Where is Zimmer Biomet headquartered?
Zimmer Biomet is headquartered at 345 East Main Street, Warsaw, Indiana 46580, USA. Warsaw, Indiana, is a major hub for the orthopedic device industry, with Zimmer Biomet as one of its anchor companies. The company operates manufacturing and distribution facilities across the United States, Europe, Asia, and Latin America.
What products does Zimmer Biomet make?
Zimmer Biomet manufactures orthopedic reconstructive products (knee, hip, shoulder, elbow replacements), sports medicine and biologics products, extremities and trauma products, craniomaxillofacial and thoracic products, bone cement, surgical products, and integrated digital and robotic technologies. Key product platforms include ROSA Robotic Solutions, Persona OsseoTi Keel Tibia, Oxford Cementless Partial Knee, Z1 Femoral Hip System, and iTaperloc Complete and iG7 Hip System with iodine-treated implants.
What are Zimmer Biomet's major acquisitions?
Zimmer Biomet's most significant acquisition was Biomet, Inc. in June 2015 for approximately $14.0 billion, which created the current company. Other major acquisitions include Centerpulse AG (2003, $3.2 billion), LDR Holding Corporation (2016, $1 billion), Paragon 28 (April 2025, $1.2 billion), OrthoGrid Systems (2024), Monogram Technologies (2025), and the iovera pain therapy business from Pacira BioSciences (2026, $140 million).
What is ZimVie?
ZimVie Inc. (NASDAQ: ZVIE) is an independent public company that was spun off from Zimmer Biomet in March 2022. ZimVie operates Zimmer Biomet's former spine and dental business. The spin-off allowed Zimmer Biomet to focus on its core orthopedic reconstructive and sports medicine businesses. ZimVie is no longer part of Zimmer Biomet.
Who is the CEO of Zimmer Biomet?
Ivan Tornos serves as Chairman, President, and CEO of Zimmer Biomet. Tornos was appointed CEO in 2023, succeeding Bryan Hanson. Under Tornos's leadership, the company has focused on its "Magnificent Seven" innovation platforms, completed three transformative acquisitions, and initiated a transition to a direct sales model in the U.S.
What is Zimmer Biomet's revenue?
Zimmer Biomet reported FY2025 (ended December 31, 2025) net sales of $8.23 billion, up 7.2% from $7.68 billion in FY2024. Net earnings were $705.1 million, and adjusted net earnings were $1.63 billion. Diluted EPS was $3.55, and adjusted diluted EPS was $8.20. For Q1 2026, net sales were $2.09 billion, up 9.3%, with net earnings of $238.1 million and diluted EPS of $1.22.
- Founded: 1927
- Headquarters: Warsaw, Indiana, USA
- Company Type: Publicly Traded
- Stock: NYSE: ZBH
- Revenue: $8.23 billion (FY2025, ended December 2025)
- Employees: ~17,000
Where Is Paragon 28 Made / Based?
- Headquarters: Englewood, Colorado, USA
- Manufacturing / Operations: United States
Paragon 28 Categories & Tags
Paragon 28 Recalls & Controversies
Paragon 28 has maintained a relatively clean regulatory record. As a medical device company regulated by the FDA, the brand is subject to stringent quality and reporting requirements.
The company has received FDA 510(k) clearances for its products, including the Gorilla Pilon Fusion Plating System and the Phantom TTC Trauma Nail, both cleared in July 2025 prior to their commercial launch in October 2025. FDA 510(k) clearance requires demonstration of substantial equivalence to a predicate device.
No major product recalls have been publicly reported for Paragon 28 devices. The company's products are classified as Class II medical devices, which require special controls but do not require the more rigorous Premarket Approval (PMA) process associated with Class III devices.
The acquisition by Zimmer Biomet in 2025 proceeded without significant regulatory controversy. The transaction received required regulatory approvals and was approved by Paragon 28 stockholders. The deal closed within the expected timeframe of the first half of 2025.
Zimmer Biomet itself has faced product-related controversies in its broader portfolio, including hip implant recalls and securities litigation in prior years, but these have not been attributed to the Paragon 28 business. Zimmer Biomet maintains compliance monitoring and quality management systems across its acquired brands.
Frequently Asked Questions About Paragon 28
Sources & Further Reading
- Zimmer Biomet: Definitive Agreement to Acquire Paragon 28
- Zimmer Biomet: Completion of Paragon 28 Acquisition
- Reuters: Zimmer Biomet to buy Paragon 28 for $1.1 billion
- MedTech Dive: Zimmer launches 2 devices from $1.1B orthopedic takeover
- Paragon 28 Official Website
- Zimmer Biomet Investor Relations
- Paragon 28: Brachiator Mini-Rail Launch
- Paragon 28: SPIDER MONKEY TTT Launch
Competitors to Paragon 28
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Zimmer Biomet | USA | 2016 | Premium | Global | All Genders |
Competitive Analysis
Market Positioning: Paragon 28 competes with 1 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Independent Alternatives to Paragon 28
Looking for brands with different ownership structures? These similar brands are not owned by Zimmer Biomet Holdings, Inc., giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsPharmacy Direct
Owned by Chempro Chemists
Australian online pharmacy operated by Chempro Chemists from Molendinar, Queensland. Offers prescription medications, health products, and wellness items through digital platforms and mail-order delivery.
online-pharmacymail-orderdigital-health
Privately Owned
Pharmacy Direct is privately owned, unlike Paragon 28 which is under a publicly traded parent company.
Healthcare PharmaceuticalsRetavase
Owned by EKR Therapeutics, Inc.
Retavase (reteplase) is a prescription thrombolytic medication indicated for acute ST-elevation myocardial infarction. Administered as two 10-unit intravenous bolus injections 30 minutes apart. Currently marketed by Chiesi USA.
pharmaceuticalthrombolyticreteplase
Privately Owned
Retavase is privately owned, unlike Paragon 28 which is under a publicly traded parent company.
Healthcare PharmaceuticalsTirosint
Owned by IBSA Institut Biochimique S.A.
IBSA Institut Biochimique SA's branded levothyroxine softgel capsule (Tirosint) and liquid solution (Tirosint-SOL), FDA approved for hypothyroidism, formulated without dyes, gluten, lactose, alcohol, or sugar, providing an excipient-free alternative to conventional levothyroxine tablets for patients with sensitivities or absorption issues.
levothyroxinehypothyroidismthyroid
Privately Owned
Tirosint is privately owned, unlike Paragon 28 which is under a publicly traded parent company.
Healthcare PharmaceuticalsPfizer
Owned by Pfizer Inc.
American multinational pharmaceutical corporation developing and manufacturing medicines, vaccines, and consumer healthcare products, one of the world's largest pharmaceutical companies.
pharmaceuticalvaccinesmedicines
Publicly Traded
Pfizer operates independently without a large parent corporation.
Healthcare PharmaceuticalsPhilips
Owned by Koninklijke Philips N.V.
Health technology brand owned by Koninklijke Philips N.V., a publicly traded Dutch company listed on Euronext Amsterdam (PHIA). Covers medical imaging, patient monitoring, and personal health products.
healthcare-technologyelectronicsmedical-devices
Publicly Traded
Philips operates independently without a large parent corporation.
Healthcare PharmaceuticalsAlcon
Owned by Alcon Inc.
Independent publicly traded global eye care company headquartered in Geneva, Switzerland, specializing in surgical equipment, contact lenses, and ophthalmic products. Spun off from Novartis in April 2019.
eye-carecontact-lensesophthalmic
Publicly Traded
Alcon operates independently without a large parent corporation.
Zimmer Biomet Holdings, Inc. Stock Information
Jobs at Zimmer Biomet Holdings, Inc.
Latest News About Paragon 28
Related Articles About Paragon 28
View more articles
Brand Comparisons
Pfizer vs Johnson & Johnson: Pharma Brand Portfolios Compared
Pfizer and Johnson & Johnson are two of the most recognizable names in healthcare. But their brand portfolios look nothing alike. Here is a complete breakdown of what each company owns, how they got there, and what sets them apart.
Who Brands StaffMar 16, 2026
PharmaceuticalPfizerJohnson And Johnson
Brand Ownership
15 Pharmacy Brands and Their Corporate Parents
CVS spent $69 billion to buy Aetna. Walgreens acquired Boots for $15 billion. Amazon paid $1 billion for PillPack. Here are 15 pharmacy brands, who owns them, and how a once-diverse industry collapsed into two dominant players.
Who Brands StaffFeb 26, 2026
Pharmacy BrandsBrand OwnershipCvs
Brand Ownership
Who Owns Your Vitamins? The Hidden Corporate Parents Behind Supplement Brands
The supplement industry is worth $60+ billion but most brands are owned by pharma giants and food conglomerates. Here is who owns every major vitamin and supplement brand.
Who Brands StaffFeb 5, 2026
VitaminsSupplementsBrand Ownership
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.
Brandpharmaceutical
Abbokinase
Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.
Brand in Healthcare & Pharmaceuticals
thrombolyticurokinase
Branddermatology
Accutane
Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.
Brand in Healthcare & Pharmaceuticals
acne-treatmentprescription
Brandpharmaceutical
Activase
Activase (alteplase) is a prescription thrombolytic medication manufactured by Genentech, a wholly-owned subsidiary of Roche. Used to treat acute ischemic stroke, heart attack, and pulmonary embolism.
Brand in Healthcare & Pharmaceuticals
thrombolyticstroke-treatment